FEMY · Femasys Inc · Investor Relations

ATLANTA, Feb. 27, 2026 (GLOBE NEWSWIRE) - Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today it has granted to two new non-executive employees who began their employment with Femasys in February 2026 options to purchase 185,000 shares of Femasys common stock. These inducement grants were granted at an exercise price per share of $0.50 and $0.57, equal to the closing price of Femasys common stock on the date of employment as reported by Nasdaq. This grant was approved by the Compensation Committee of Femasys’ Board of Directors and made as an inducement material to employment to individuals hired by Femasys. The stock options will vest as to 25% of the shares underlying the stock option on the first anniversary of the commencement of employment, with the remaining shares vesting 25% each year over the following three years, subject to continued

- FemBloc becomes the latest Femasys product to achieve MDSAP certification, building on a proven track record of compliance - ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) - Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today that its FemBloc permanent birth control system has achieved certification under the Medical Device Single Audit Program (MDSAP). The MDSAP certification positions the Company to accelerate regulatory and commercial execution across key global markets, including the United States, Canada, Japan, Australia, and Brazil. In the U.S., FDA recognition of MDSAP reflects a high level of quality system maturity and supports regulatory readiness as the Company advances its pivotal clinical trial toward PMA submission. Internationally, the certification enhances manufacturing credibility and operational scalability, supporting ongoing

- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment - ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) - Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today that it has received notice from the American Medical Association (AMA) CPT Editorial Panel approving a new, unique Category III Current Procedural Terminology (CPT) code covering the use of FemaSeed for intratubal insemination (ITI), a procedure that delivers sperm directly into the fallopian tube where conception occurs. The approved Category III CPT code is expected to be issued publicly by the AMA with an effective date of January 1, 2027. Approval of this Category III CPT code represents an important step in advancing the reimbursement strategy for FemaSeed to support broader clinical adoption, provider utilization, and expanded patient access to

- Multi-Product Distribution Agreement Marks Continued Commercial Momentum in Europe - ATLANTA, Feb. 03, 2026 (GLOBE NEWSWIRE) - Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a new strategic distribution partnership with OR Consulting to support the commercial launch of its product portfolio in Switzerland. The agreement includes FemBloc Permanent Birth Control, FemaSeed Intratubal Insemination, and additional Femasys fertility and women’s diagnostic health products. Together with the Company’s recent market entry in Spain and the ongoing commercial launch in France, this partnership represents continued execution of Femasys’ European expansion strategy and broadens access to its innovative technologies through experienced regional partners. “Expanding into Switzerland with OR Consulting further strengthens our European commercial platform and

ATLANTA, Jan. 14, 2026 (GLOBE NEWSWIRE) - Femasys Inc. (NASDAQ: FEMY) (“Femasys” or the “Company”), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, today announced that on January 13, 2026, it received notification from The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq approved the Company's request for an additional 180-calendar day extension to regain compliance with the minimum closing bid price requirement of US$1.00 per share. The Company now has until July 13, 2026 to regain compliance, as set forth in Nasdaq Listing Rule 5550(a)(2). Nasdaq's extension notice has no immediate effect on the continued listing status of the Company's common stock on The Nasdaq Capital Market LLC under the symbol "FEMY". If at any time during the additional 180-day extension, the bid price of the Company's common stock closes at, or above, $1.00 per share for a minimum of ten consecutive business days,

Partnership enables broader adoption of FemaSeed through a trusted community health provider serving a large, engaged patient population ATLANTA , Jan. 13, 2026 (GLOBE NEWSWIRE) - Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a partnership with Refuah Health Center to offer FemaSeed as a first step in the infertility treatment process. The partnership is expected to strengthen Femasys’ commercial footprint in community-based fertility care by expanding patient access and supporting increased utilization of FemaSeed as a first-line approach. “This partnership is an important step forward in expanding the commercial availability of FemaSeed within community-based fertility care,” said Kathy Lee-Sepsick, Chief Executive Officer of Femasys. “With Refuah’s trusted care model and strong patient engagement, we expect to accelerate adoption of FemaSeed